Browse > Article
http://dx.doi.org/10.12701/yujm.2020.00878

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab  

Choi, Sujin (Department of Pediatrics, School of Medicine, Kyungpook National University)
Choi, Bong Seok (Department of Pediatrics, School of Medicine, Kyungpook National University)
Choe, Byung-Ho (Department of Pediatrics, School of Medicine, Kyungpook National University)
Kang, Ben (Department of Pediatrics, School of Medicine, Kyungpook National University)
Publication Information
Journal of Yeungnam Medical Science / v.38, no.3, 2021 , pp. 251-257 More about this Journal
Abstract
Vedolizumab (VDZ) has been approved for the treatment of inflammatory bowel diseases (IBDs) in patients aged ≥18 years. We report a case of a pediatric patient with Crohn disease (CD) who was successfully treated with VDZ. A 16-year-old female developed severe active pulmonary tuberculosis (TB) during treatment with infliximab (IFX). IFX was stopped, and TB treatment was started. After a 6-month regimen of standard TB medication, her pulmonary TB was cured; however, gastrointestinal symptoms developed. Due to the concern of the patient and parents regarding TB reactivation on restarting treatment with IFX, VDZ was started off-label. After the second dose of VDZ, the patient was in clinical remission and her remission was continuously sustained. Ileocolonoscopy at 1-year after VDZ initiation revealed endoscopic healing. Therapeutic drug monitoring conducted during VDZ treatment showed negative antibodies to VDZ. No serious adverse events occurred during the VDZ treatment. This is the first case report in Korea demonstrating the safe and effective use of VDZ treatment in a pediatric CD patient. In cases that require recommencement of treatment with biologics after recovery of active pulmonary TB caused by anti-tumor necrosis factor agents, VDZ may be a good option even in pediatric IBD.
Keywords
Child; Inflammatory bowel diseases; Infliximab; Tuberculosis; Vedolizumab;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr 2015;169:1053-60.   DOI
2 Kang B, Choe YH. Early biologic treatment in pediatric Crohn's disease: catching the therapeutic window of opportunity in early disease by treat-to-target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11.   DOI
3 Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.   DOI
4 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res 2018;16:4-16.   DOI
5 Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75.   DOI
6 Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-27.   DOI
7 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res 2018;16:17-25.   DOI
8 Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017;66:839-51.   DOI
9 Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2121-6.   DOI
10 Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Med 2019;17:89.   DOI
11 Lowenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn's disease. Gastroenterology 2019;157:997-1006.   DOI
12 Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018;16:1937-46.   DOI
13 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization andEuropean Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91.   DOI
14 Abreu C, Magro F, Santos-Antunes J, Pilao A, Rodrigues-Pinto E, Bernardes J, et al. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis 2013;7:e486-92.   DOI
15 Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN. J Crohns Colitis 2017;11: 1230-7.   DOI
16 Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, et al. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease. Gastroenterology 2018;155:687-95.   DOI
17 Aardoom MA, Jongsma MM, de Vries A, Wolthoorn J, de Ridder L, Escher JC. Vedolizumab trough levels in children with anti-tumor necrosis factor refractory inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2020;71:501-7.   DOI
18 Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal healing in paediatric patients with moderate-to-severe luminal crohn's disease under combined immunosuppression: escalation versus early treatment. J Crohns Colitis 2016;10:1279-86.   DOI
19 Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.   DOI
20 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2021;15:171-94.   DOI